Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength

• Omlyclo^® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by year-end
• Omlyclo^® 300 mg strength available in both pre-filled syringe (PFS) and autoinjector (AI) presentations
• Multiple dose strengths and device options broaden treatment flexibility for healthcare professionals

INCHEON, South Korea--(BUSINESS WIRE)--Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo^® (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in Europe.¹ With the addition of the 300 mg strength, Celltrion has expanded its Omlyclo^® portfolio to include multiple dose strengths and device presentations for patients, healthcare professionals and healthcare institutions.

Following the European launch of Omlyclo^® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength in key markets including Germany, the UK and France in the middle of this year. Celltrion is gradually expanding supply to other European countries and plans to complete the rollout across Europe by the end of the year.

Celltrion is offering Omlyclo^® 300 mg in both pre-filled syringe (PFS) and autoinjector (AI) presentations, allowing patients and healthcare professionals a choice of device depending on the treatment setting and individual patient needs. This comprehensive portfolio provides greater flexibility in dose strengths and device options.

Celltrion will continue to provide product information to healthcare professionals and institutions as part of its commercial activities across Europe.

“The launch of Omlyclo^® 300 mg allows us to offer patients and healthcare professionals more convenient and flexible treatment options,” said Taehun Ha, Senior Vice President and Head of Europe at Celltrion. “Building on the first omalizumab biosimilar¹ advantage and broad product portfolio, we will continue to strengthen our competitive position in key tenders and work to sustain Omlyclo^®’s strong growth momentum across Europe throughout the second half.”

About OMLYCLO^® (CT-P39, biosimilar omalizumab¹)

Omlyclo^® is the first European Commission (EC) approved anti-IgE antibody biosimilar referencing Xolair^® (omalizumab). In the EU, Omlyclo^® is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP).

About Celltrion, Inc.

Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, haematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us and stay updated with our latest news and events on our social media - LinkedIn, Instagram, X, and Facebook.

FORWARD-LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as "prepares", "hopes to", "upcoming", "plans to", "aims to", "to be launched", "is preparing", "once gained", "could", "with the aim of", "may", "once identified", "will", "working towards", "is due", "become available", "has potential to", “anticipates”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements.

Celltrion, Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

Trademark

Xolair^® is a registered trademark of Novartis AG.

Reference

¹ European Medicines Agency. Summary of Product Characteristics (SmPC), Omlyclo. [Last Accessed August 2026]